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Objectives: Investigate the prevalence of obesity in
Italy and examine its resource consumption and
economic impact on the Italian national healthcare
system (NHS).
Design: Retrospective, observational and real-life study.
Setting: Data from three health units from Northern
(Bergamo, Lombardy), Central (Grosseto, Tuscany) and
Southern (Naples, Campania) Italy.
Participants: All patients aged ≥18 years with at least
one recorded body mass index (BMI) measurement
between 1 January 2009 and 31 December 2012 were
included.
Interventions: Information retrieved from the
databases included primary care data, medical
prescriptions, specialist consultations and hospital
discharge records from 2009–2013. Costs associated
with these data were also calculated. Data are presented
for two time periods (1 year after BMI measurement and
study end).
Primary and secondary outcome measures:
Primary—to estimate health resources consumption and
the associated economic impact on the Italian NHS.
Secondary—the prevalence and characteristics of
subjects by BMI category.
Results: 20 159 adult subjects with at least one
documented BMI measurement. Subjects with BMI
≥30 kg/m2 were defined as obese. The prevalence of
obesity was 22.2% (N=4471) and increased with age.
At the 1-year observation period, obese subjects who
did not receive treatment for their obesity experienced
longer durations of hospitalisation (median length:
5 days vs 3 days), used more prescription drugs
(75.0% vs 57.7%), required more specialised outpatient
healthcare (mean number: 5.3 vs 4.4) and were
associated with greater costs, primarily owing to
prescription drugs and hospital admissions (mean
annual cost per year per patient: €460.6 vs €288.0 for
drug prescriptions, €422.7 vs € 279.2 for
hospitalisations and €283.2 vs €251.7 for outpatient
care), compared with normal weight subjects. Similar
findings were observed for the period up to data cut-off
(mean follow-up of 2.7 years).
Conclusions: Untreated obesity has a significant
economic impact on the Italian healthcare system,
highlighting the need to raise awareness and proactively
treat obese subjects.
INTRODUCTION
Obesity is now widely regarded as a global epi-
demic; worldwide, obesity rates have more
than doubled since 1980.1 2 According to the
WHO, more than 19 billion adults were over-
weight in 2014. Of these, over 600 million
(∼13% of the world’s population) were
obese, deﬁned as having a body mass index
(BMI) of ≥30 kg/m2.1 In Italy, WHO reports
from 2014 showed that the prevalence of
obesity was 20.4% among individuals aged
≥18 years.3 Obesity is a major risk factor for
various chronic diseases, particularly if it
remains untreated. Globally, 44% of diabetes,
23% of ischaemic heart disease and 7–41% of
certain cancers are attributable to being over-
weight or obese.1 Obesity-associated mortality
rates are also alarmingly high, with at least 2.8
million deaths each year resulting from being
overweight or obese.1 Obesity was once con-
sidered to be an issue associated with high-
income countries only; however, its preva-
lence is now also increasing in low-income
and middle-income countries.4
Previous studies have shown that obesity
and its associated comorbidities have a
Strengths and limitations of this study
▪ Large study on more than 20 000 subjects;
▪ Real-world data coming from local health units;
▪ Data retrieved from different geographical areas;
▪ Direct evaluation of costs by integrating multiple
data sources
▪ Limitations due to the retrospective nature of the
study.
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considerable economic impact on healthcare systems,
primarily because of high costs for medication and hos-
pitalisations.5–8 However, in those studies, costs were
only estimated indirectly. In contrast, we report here on
the ﬁndings from a study of over 20 000 adults that inves-
tigated the prevalence of, and direct costs associated
with, untreated obesity in three distinct regions of Italy
—which differ in terms of geography and nutritional tra-
ditions—in order to understand the healthcare usage
and economic impact of obesity on the Italian national
healthcare system (NHS).
METHODS
Study design and population
This was a retrospective, observational and real-life study.
To be eligible, individuals were required to be aged
≥18 years and to have at least one recorded BMI meas-
urement between 1 January 2009 and 31 December
2012. The ﬁrst recorded BMI was set as the index date.
Eligible subjects were identiﬁed from registries at three
Italian local health units that represent the primary
Italian geographical areas: Bergamo, Lombardy (north-
ern Italy), Grosseto, Tuscany (central Italy) and Naples,
Campania (southern Italy).
BMI was classiﬁed as follows: underweight, <18.5
kg/m2; normal weight, ≥18.5 to <25 kg/m2; overweight,
≥25 to <30 kg/m2 and obese, ≥30 kg/m2. Obesity was
further classiﬁed as grade I, II and III based on BMI levels
of ≥30 to <35 kg/m2, ≥35 to <40 kg/m2 and ≥40 kg/m2,
respectively.9
An anonymous data ﬁle is routinely used by regional
health authorities for epidemiological and administrative
purposes. No identiﬁers related to subjects were pro-
vided to the researchers. In accordance with Italian law
regarding data conﬁdentiality,10 the ethics committee of
each local health units was notiﬁed about the study.
Study objective
The primary objective of the study was to estimate
health resource consumption and the economic impact
of obesity on the Italian NHS. The secondary objective
was to assess the prevalence and characteristics of sub-
jects in relationship with the BMI category.
Data sources and analysis
Primary care data for each subject were retrospectively
collected from the Health Search Database of the
Società Italiana di Medicina Generale (Italian Society of
General Medicine) for the period 2009–2013. Using the
numeric code assigned to each citizen by the local
health units as a unique identiﬁer, this database was
linked to the following databases: (1) Medications
Prescription Database, which includes anatomical–thera-
peutic–chemical (ATC) codes; (2) Hospital Discharge
Database, which includes dates of hospital admission
and discharge, as well as discharge diagnosis codes
according to the International Classiﬁcation of Diseases
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM); (3)
Laboratory Tests and Specialist Visits Database; (4)
Mortality Database, from which data on mortality, but
not cause of death, were collected and (5) Beneﬁciaries’
Database, from which data regarding date of birth, sex
and place of residence were collected.
Data on drug use, hospitalisations, use of specialist ser-
vices and treatment costs were evaluated from the index
date until 31 December 2013, corresponding to a period
of at least 12 months and up to 5 years (the date of last
enrolment was 31 December 2012). Specialist services
encompassed all specialised outpatient healthcare, includ-
ing diagnostic and laboratory tests (such as X-ray, ultra-
sound, MRI, blood and urinary tests), and consultations
by specialist healthcare providers. The cost analysis was
conducted from the perspective of the NHS. Costs are
reported in Euros (€). Drug costs were evaluated based
on the Italian NHS costs at the time of the analysis.
Outpatient services costs were evaluated according to
regional tariffs. Hospitalisation costs were calculated using
the diagnosis-related group tariff. Data were presented
according to BMI class for the normal weight, overweight
and obese (total and grade I, II and III) cohorts for two
time periods: at 1 year following the index date (1-year
observation period) and at the time of data cut-off (31
December 2013). Underweight subjects were included for
the prevalence analysis only. Costs were also analysed
according to age (using a cut-off of 65 years).
Statistical analysis
To test the normality of data distribution, the skewness–
kurtosis test was used. Continuous variables were
reported as mean and SD or median and IQR, as appro-
priate, and compared with analysis of variance (ANOVA)
test, whereas categorical variables were expressed as
numbers and percentages, and compared with the χ2
test. Analyses were performed stratiﬁed for BMI groups.
p≤0.05 was considered statistically signiﬁcant. All statis-
tical analyses were conducted using Stata software V.120
(Stat Corp LP, College Station, Texas, USA), data man-




Overall, 20 159 adults were included in the study.
Table 1 shows the characteristics of subjects who were
classiﬁed as underweight, normal weight, overweight
and obese at the index date. The prevalence of obesity
was 22.2% (N=4471); of these, 3253 (72.8%) were classi-
ﬁed as grade I obesity, 898 (20.1%) as grade II obesity
and 320 (7.2%) as grade III obesity. The mean length of
follow-up was 2.6, 2.7 and 2.8 years for the normal
weight, overweight and obese groups, respectively
(p=NS). Within the obese group, the mean length of
follow-up was 2.8 years across each of the grade I, II and
III obesity cohorts; 1.1% of subjects died at 1 year
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following the index date (normal weight 1.1%, over-
weight 1.2% and obese 1.1%; p=NS).
Prevalence of obesity by age
The proportion of subjects who were overweight or
obese increased with age, while it decreased for normal
weight subjects (p<0.001) (table 2). Among subjects
aged >30 years, more than half were classiﬁed as over-
weight or obese (table 2). In particular, among subjects
aged between 30 and 64 years, 36.4 and 22.8% were
overweight and obese, respectively; among subjects aged
65+ years, 44.2 and 23.7% were overweight and obese,
respectively (table 2).
Use of prescription medication
In total, 13 002 subjects from the normal weight, over-
weight and obese groups (66%) received at least one pre-
scription drug treatment during the 1-year observation
period. 3353 were obese subjects (75%), 4437 were
normal weight subjects (57.7%) and 5212 were overweight
subjects (69.1%). These differences were signiﬁcant
(p<0.0001 among groups); 14 807 (75.2%) subjects had
received at least one drug treatment at data cut-off; 3666
were obese subjects (82%), 5276 were normal weight sub-
jects (68.6%) and 5865 were overweight subjects (77.7%).
Again, these differences were signiﬁcant (p<0.0001
among groups). During the 1-year observation period,
antihypertensive drugs were the most common drug class
received (43.8% of subjects); 31.3% of subjects received
gastrointestinal drugs, 28.8% received anti-inﬂammatory
drugs, 23.4% received antiplatelet drugs, 17.7% received
statins and 0.7% received antineoplastic drugs. Obese
patients received each class of drug more frequently than
normal weight or overweight subjects (p<0.001 for all drug
classes except antineoplastic among all groups and statins
between overweight and obese subjects (p=NS)) (ﬁgure
1A). The largest difference in drug use between subjects
who were obese and of normal weight was observed for
the antidiabetic drug class (30.1% increase in obese sub-
jects; p<0.001). Results were similar for the period up to
data cut-off (p<0.001 for all drug classes except antineo-
plastic among all groups and statins between overweight
and obese subjects (p=NS)) (ﬁgure 1B).
Duration of hospitalisation
In total, 1416 subjects (7.2%) were hospitalised at least
once during the 1-year observation period and this
increased to 3204 subjects (16.3%) for the period up to
data cut-off. In normal weight, overweight and obese
subjects, hospitalisation rates were 6.5%, 7.7% and 7.6%,
respectively, at 1 year, and 14.8%, 17.3% and 17.0%,
respectively, at data cut-off. Obese and overweight sub-
jects had a higher hospitalisation rate in comparison
with normal weight individuals (p=0.006 and 0.03, at
1-year follow-up and data cut-off, respectively). In the
1-year observation period, the mean duration of hospi-
talisation was 3 (IQR 7) days in normal weight subjects,
4 (IQR 7) days in overweight subjects and 5 (IQR 8)
days in obese subjects (p=NS). Within the group of
obese subjects, median duration of hospitalisation was
not different among the grade III (4.5 (IQR 8) days),
grade I (5 IQR 8) days) and grade II obese (4.5 (IQR
9.5) days) groups. The most common reasons for hospi-
talisation in the grade I and II obese groups were type 2








to <30) Obese (BMI ≥30) Total
Patients, n (%) 457 (2.3) 7686 (38.1) 7545 (37.4) 4471 (22.2) 20 159 (100)
Males:females, n:n 67:390 2977:4709 3996:3549 2048:2423 9088:11 071
Mean age±SD, years 44.6±20.4* 53.6±17.2† 59.3±15.2‡ 58.1±15.1 56.5±16.4
*p<0.001 vs normal weight, overweight and obese.
†p<0.001 vs overweight and obese.
‡p<0.001 vs obese.
BMI, body mass index; SD, standard deviation.
Table 2 Proportions of patients classified as being of normal weight, overweight and obese, stratified by age at the index
date
Prevalence Normal weight Overweight Obese Total
18–29 years, n (%) 743 (62.0)* 267 (22.3)* 189 (15.8)* 1199 (100.0)
30–64 years, n (%) 4701 (40.8)† 4195 (36.4)† 2627 (22.8)† 11 523 (100.0)
65+ years, n (%) 2242 (32.1) 3083 (44.2) 1655 (23.7) 6980 (100.0)
Total 7686 7545 4471
*p<0.0001 vs 30–64 years and +65 years.
†p<0.0001 vs +65 years.
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diabetes and essential hypertension (not speciﬁed; 0.8%
each). For grade III obese patients, the most common
reasons for hospitalisation were severe obesity and
benign essential hypertension (1.6% and 0.9%, respect-
ively). Similarly, the median duration of hospitalisation
for the period up to data cut-off did not show signiﬁcant
differences among groups (obese subjects, 5 (IQR 7)
days; normal weight subjects, 3 (IQR 7) days and over-
weight subjects, 4 (IQR 7) days, respectively; p=NS), as
well as among obese subgroups (grade I obesity 4
(IQR 7) days; grade II obesity 5 (IQR 9) days and
grade III obesity 5 (IQR 7.5) days; p=NS).
Figure 1 Patients exposed to
treatment, by BMI category and
drug class, during (A) the 1-year
observation period and (B) the
period up to data cut-off. (A)
*p<0.001 vs overweight and
obese subjects; †p<0.001 vs
obese subjects. (B) *p<0.001 vs
overweight and obese subjects;
†p<0.001 vs obese subjects.
BMI, body mass index.
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Use of specialist services
During the 1-year observation period, an average of 5.3
(±7.0) specialist services were required overall for obese
subjects; the mean number of specialist services required
was higher in the grade II obese group (5.8±9.5) than
in the other BMI groups (4.4±5.5, 5.0±7.2, 5.2±6.3 and
5.0±5.8 for normal weight, overweight, grade I obese and
grade III obese groups, respectively, p<0.001). At the point
of data cut-off, the mean number of specialist services
required was 18.8 (±26.8) in the grade II obese group
compared with 12.7 (±16.1), 15.8 (±21.3), 16.6 (±18.8)
and 15.9 (±18.5) for the normal weight, overweight, grade
I and III obese groups, respectively (p<0.001).
Costs
During the observation period, the mean annual health-
care costs per subject were €819.03 for the normal
weight group, €1015.19 for the overweight group and
€1166.52 for the obese group, respectively. The mean
healthcare cost per subject for the period up to data
cut-off was €2465.01 for the normal weight group,
€3417.81 for the overweight group and €3782.21 for the
obese group, respectively. Mean healthcare costs during
the 1-year observation period were higher in obese than
in non-obese subjects (p<0.001), while no differences
were observed at data cut-off point (p=NS) (ﬁgure 2A,
B). During the 1-year observation period, the highest
Figure 2 Mean annual costs per
surviving individual, by BMI
category, during (A) the 1-year
observation period and (B) the
period up to data cut-off. (A)
Overall costs: p<0.001 vs
overweight and obese subjects;
p<0.01 vs grade I and grade II
obese subjects. Drug costs:
p<0.001, p<0.01; Hospitalisation
costs: p<0.01, p=NS;
Outpatient costs: p<0.01, p=NS.
(B) Overall costs: p<0.001 vs
overweight and obese subjects;
p<0.01 vs grade I and grade II
obese subjects. Drug costs:
p<0.001, p=NS; Hospitalisation
costs: p<0.001, p=NS; Outpatient
costs: p<0.001, p<0.05. BMI,
body mass index.
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mean annual costs per individual in the obese group
were associated with drug prescriptions (€461), followed
by hospitalisation costs (€423) and specialised outpatient
services (€283). Subjects with grade II obesity generated
higher costs than the grade I and grade III obese
groups, primarily owing to higher hospitalisation costs
(p<0.01). Compared with normal weight controls over
1 year, costs were higher by 23.5% for overweight sub-
jects (34.3% when considering drug costs only), 34.8%
for patients with grade I obesity (47.0% for drug costs
only), 70.4% for those with grade II obesity (90.1% for
drug costs only) and 33.9% for patients with grade III
obesity (83.9% for drug costs only) (all values: p<0.01).
At the point of data cut-off, the mean annual costs in the
obese group had increased to €1544.24 for drug prescrip-
tions, €1256.41 for hospitalisation costs and €981.56 for
outpatient services (ﬁgure 2B). Similar to the 1-year obser-
vation, costs were higher for obese patients in comparison
with normal weight controls (p<0.01) (ﬁgure 2B). Again,
patients with grade II obesity generated higher costs,
mainly due to outpatient costs (p<0.05) (ﬁgure 2B).
The possible effect of age, when comparing the
impact of obesity on healthcare costs, is reported in
ﬁgure 3.
DISCUSSION
There are still limited data on healthcare resources usage
for untreated obesity and its economic impact on health-
care systems. We report here on the prevalence and asso-
ciated costs of obesity in an Italian population of over
20 000 individuals. Our study represents one of the
largest European population studies on obesity and pro-
vides a real-life assessment of the economic impact of this
increasingly prevalent condition. The ﬁndings of our
study show that obese adults who did not receive
treatment for their underlying obesity used more pre-
scription drugs, experienced longer durations of hospital-
isation, required more specialised outpatient healthcare
and were associated with substantially greater costs com-
pared with normal weight adults.
Our study directly evaluated the economic impact of
comorbidities associated with obesity on the Italian
healthcare system by integrating multiple data sources,
taking into account the true costs of pharmaceutical
treatments, the use of diagnostic and specialist services
and hospitalisations over a period of up to 5 years.
Importantly, as a result of the structure of the Italian
NHS and the multiple data sources available, the health-
care resources and costs reported in this study are a true
and accurate reﬂection of the real-life costs for each
subject. To the best of our knowledge, at present only
few studies have evaluated data on real-life healthcare
costs from obesity associated with BMI.11–13 Previous
studies have been limited by the fact that they were
based on resources used at a single point in time or
restricted to a single hospital department. Our study in
a real-world setting helps to identify the actual consump-
tion of resources by obese patients. However, as with any
retrospective observational study, it should be noted that
limitations might exist as a result of the variability of
professional practice and information bias.
Obese subjects used a wide range of drugs, including
antihypertensive, gastrointestinal, anti-inﬂammatory, anti-
platelet and antidiabetic drugs. Our study showed that
obese subjects generally received each class of drug more
frequently than normal weight or overweight subjects, with
the exception of antidepressants. This is likely to reﬂect the
various comorbidities that obese subjects commonly experi-
ence if their underlying condition remains untreated, such
as diabetes and hypertension. Notably, antidiabetic and
antihypertensive drugs were used in around twice as many
Figure 3 Mean cost according
to age and BMI. BMI, body mass
index.
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obese as normal weight subjects. Overall healthcare costs
were substantially higher for obese than for non-obese indi-
viduals. Prescriptions represented the greatest overall costs,
highlighting the economic impact that obesity-related
comorbidities have on healthcare systems.
There were also signiﬁcant costs associated with hospi-
talisation, particularly for the grade II obese group; this
may be related to the longer mean duration of hospital-
isation in these patients compared with grade III obese
and non-obese subjects. The relatively short hospital stay
observed in the grade III obesity group should be high-
lighted as this may suggest that many institutions within
the Italian healthcare system are not adequately
equipped to diagnose and treat morbidly obese subjects,
such as radiological instruments not being suitable to
host severely obese patients, or a lack of specialists with
sufﬁcient experience to prescribe suitable therapies to
address the different comorbidities. This could result in
these patients being discharged from hospital earlier
than should be expected. It is also possible that, as
severely obese people are frequently depressed,14–16 they
may refuse to leave home to go to hospital at all, unless
they have an acute condition.
The prevalence of obesity reported in this study
(222%) is in line with the current WHO estimation of
the prevalence of obesity in Italy (210%),3 but higher
than other estimates (∼10%).17 18 The proportion of sub-
jects who were overweight or obese increased with age,
with more than half of adults aged ≥30 years being over-
weight or obese. Similar ﬁndings have previously been
reported in Italy;19 based on data from ﬁve surveys con-
ducted between 2006 and 2010, the prevalence ratios for
overweight/obesity in individuals aged ≥65 vs 18–24 years
were 201 in men and 265 in women.17 These data
suggest that it may be important to target and educate
individuals who are overweight or have grade I obesity
and are of working age, with the aim of preventing them
from becoming more obese later in life.
Since older subjects are likely to consume more
healthcare resources, we have also analysed the possible
effect of age when comparing the impact of obesity on
healthcare costs. The results highlight that healthcare
costs did not increase just because obese patients were
older than normal weight patients, but that in each age
group, the costs of obese patients were higher than
other patients.
It is important to raise awareness that the direct treat-
ment of patients who are severely obese would help to
reduce the economic impact of the condition on health-
care systems.20 The initial costs associated with treat-
ment, such as bariatric surgery, would probably be offset
by the subsequent savings made on drug prescriptions,
hospitalisation costs and outpatient care related to the
treatment of comorbidities.21 22 Indeed, a recent
meta-analysis, comprising 37 720 patients across 11
studies, showed that bariatric surgery signiﬁcantly
reduces drug use and costs.23 In addition, the direct
treatment of obesity would likely help to reduce the
burden on physicians who spend a substantial amount
of time treating the comorbidities associated with
obesity. The value of preventative strategies for obesity is
an important consideration for decision makers, particu-
larly given the increasing concern over the sustainability
of the healthcare system and the ageing population.
Measures such as advocating the value of a healthy and
balanced diet with regular exercise as part of an early
obesity prevention strategy are likely to be important.
Although in our study we used the healthcare data-
bases of Lombardy, Tuscany and Campania, three Italian
regions localised from north to south of Italy, including
data for a total population of about 2.3 million, and the
Health Search Database of the Società Italiana di
Medicina Generale, larger studies are needed to
conﬁrm and to enhance the generalisability of the
ﬁndings.
In conclusion, our data highlight the need to develop
public health policies that aim to prevent the develop-
ment of obesity at an early age and also to proactively
and effectively treat severely obese patients, thereby
reducing the overall economic burden of this condition.
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